| Expression pattern: |
UP |
| Associated gene: |
Wnt2b, beta-catenin, METTL3, FTO, YTHDF1/2 |
| Associated microRNA: |
miR-103a-2-5p, miR-660-3p |
| Biological function: |
sustains sorafenib resistance and inhibits sorafenib-induced apoptosis |
| Molecular mechanism: |
Acts as a miRNA sponge (ceRNA) for miR-103a-2-5p and miR-660-3p to activate Wnt2b/beta-catenin signaling; m6A modification increases circRNA-SORE stability. |
| Biological pathway or process: |
Wnt/beta-catenin (promotes); apoptosis (inhibits); chemoresistance (promotes); m6A modification (promotes) |
| Detected method: |
Q
|
| Validation methods: |
RT-qPCR; Back-Splice Junction PCR / divergent primers PCR; RNase R Treatment; Sanger Sequencing; FISH / smFISH; Actinomycin D / DRB Stability Assay; Transfection; RNA Pull-Down; RIP (RNA Immunoprecipitation); Luciferase Reporter Assay; Western Blot; CCK8; Colony Formation Assay; In Vivo Animal Model; IHC (Immunohistochemistry); Survival Analysis; Bioinformatics Analysis |
| Clinical significance: |
Lower circRNA-SORE expression is associated with better recurrence free survival and overall survival in HCC patients (including sorafenib-treated cohort). |
| Description: |
circRNA-SORE is up-regulated in sorafenib-resistant HCC and is required to maintain resistance by suppressing sorafenib-induced apoptosis. It acts as a ceRNA that sponges miR-103a-2-5p and miR-660-3p, thereby activating Wnt2b/beta-catenin signaling. Its elevated abundance in resistant cells is promoted by m6A-dependent stabilization, and targeting it in vivo enhances sorafenib efficacy. |
| Confidence score: |
0.8729 |